PubRank

Martin Jädersten

Author PubWeight™ 13.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007 2.39
2 Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol 2008 1.83
3 Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007 1.64
4 The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS One 2008 1.52
5 Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica 2011 1.15
6 Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion. Haematologica 2010 0.87
7 Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006 0.87
8 Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. J Clin Oncol 2013 0.83
9 Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 2009 0.83
10 Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome. Br J Haematol 2011 0.80
11 Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring. Haematologica 2011 0.76